Edward Licitra, MD
Medical Oncology · East Brunswick, NJNPI 1538139548
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Cornerstone Specialty Network LLC at 45.4% of the total. Reporting peaked in 2019 at $11,173 and has fallen 91.3% since, to $973 in 2025.
Across 82 payments — averaging $365.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$14K
- Daiichi Sankyo Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Janssen Scientific Affairs, LLC$2K
- Mirati Therapeutics, Inc.$1K
- Seagen Inc.$750
- plus $4K from 26 others
Across 18 payments — averaging $11,733 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$195K
- E.r. Squibb & Sons, L.L.C.$16K
What the payments were for
- Consulting fees$8,76029%
- Speaking & faculty fees$12,25041%
- Travel & lodging$3,36011%
- Food & beverage$5,51918%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cornerstone Specialty Network LLC | 12 | $13,610 |
| Daiichi Sankyo Inc. | 11 | $5,827 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,777 |
| Janssen Scientific Affairs, LLC | 1 | $2,020 |
| Mirati Therapeutics, Inc. | 2 | $1,270 |
| Seagen Inc. | 1 | $750 |
| ASD Specialty Healthcare, LLC | 8 | $553 |
| Avyxa Pharma, LLC | 3 | $428 |
| Adaptive Biotechnologies Corporation | 5 | $363 |
| Foundation Medicine, Inc. | 1 | $300 |
| E.r. Squibb & Sons, L.L.C. | 5 | $245 |
| Caris MPI, Inc. | 1 | $212 |
| Tempus AI, Inc | 3 | $188 |
| Karyopharm Therapeutics Inc. | 4 | $156 |
| Cardinal Health 110 LLC | 1 | $150 |
| Amgen | 3 | $147 |
| Exelixis Inc. | 1 | $128 |
| Epizyme, Inc. | 1 | $125 |
| Bayer | 1 | $125 |
| Servier Pharmaceuticals LLC | 1 | $121 |
| Bristol Myers Squibb | 1 | $95 |
| Blueprint Medicines Corporation | 1 | $93 |
| AstraZeneca | 2 | $46 |
| Astellas Pharma US Inc | 2 | $38 |
| Cardinal Health 108 LLC | 1 | $37 |
| AbbVie | 2 | $35 |
| Novartis | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Secura Bio, Inc. | 1 | $18 |
| Verastem, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$5,603
- NINLARO$2,750
- KRAZATI$1,250
- KYXATA$367
- AVGEMSI$367
- FRINDOVYX$367
- FOUNDATIONACT$300
- FOUNDATIONFOCUS$300
- FOUNDATIONONE CDX$300
- FOUNDATIONONE HEME$300
- FOUNDATIONONE$300
- clonoSEQ$254
- MI CANCER SEEK$212
- Cabometyx$128
- TAZVERIK$125
- XPOVIO$125
- Vitrakvi$125
How this compares
$29,948 in reported general payments places this provider in the 85th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 20 | $286,937 |
| Lupron DepotLeuprolide Acetate | 24 | $138,815 |
| NeulastaPegfilgrastim | 13 | $128,587 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $96,409 |
| ProcritEpoetin Alfa | 18 | $33,506 |
| OrgovyxRelugolix | 11 | $31,179 |
| Abiraterone Acetate | 22 | $15,580 |
| EliquisApixaban | 12 | $9,008 |
| Letrozole | 13 | $537 |
| Hydroxyurea | 15 | $521 |
| Prednisone | 33 | $282 |
| Dexamethasone | 12 | $249 |
| Warfarin Sodium | 36 | $213 |
| Escitalopram Oxalate | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $46 | $286,93720 claims |
| AbbVieLupron Depot | $35 | $138,81524 claims |
| AmgenNeulasta | $147 | $128,58713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $2,777 | $96,40922 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,020 | $15,58022 claims |
| PfizerEliquis | $19 | $9,00812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in East Brunswick
- Michael NissenblattEast Brunswick$15K
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.